

## Big Pharma Sees Amicus Support After Spending Nearly \$4.8 Million On Contributions In Recent Years

In July 2024, Bristol Myers Squibb And Johnson & Johnson Filed An Appeal With The U.S. Court Of Appeals For The Third Circuit Seeking To Overturn An April 2024 Ruling That Threw Out Their Lawsuits To Block The Medicare Drug Negotiation Program.

In April 2024, New Jersey Federal Judge Zahid Quraishi Dismissed Lawsuits From Bristol Myers Squibb And Johnson & Johnson Seeking To Block The Medicare Drug Negotiation Program...

April 2024: New Jersey Federal Judge Zahid Quraishi Dismissed Lawsuits From Bristol Myers Squibb And Johnson & Johnson Seeking To Block The Medicare Drug Negotiation Program, Stating "Selling To Medicare Is A Choice Plaintiffs Can Accept Or Not Accept." "On Monday, a New Jersey federal judge tossed lawsuits by Bristol Myers Squibb and Johnson & Johnson, which questioned the constitutionality of the U.S. government requiring drugmakers to negotiate with Medicare on the pricing of their products. [...] In his written opinion on Monday, Judge Zahid Quraishi rejected the claim of BMS and J&J that the new drug pricing program is an unconstitutional taking of their assets. 'Selling to Medicare is a choice plaintiffs can accept or not accept,' Quraishi wrote. '[It] may be less profitable than it was before the institution of the program, but that does not make the defendants' decision to participate any less voluntary.'" [FiercePharma, 04/30/24]

...But In July 2024, Bristol Myers Squibb And Johnson & Johnson Filed An Appeal With The U.S. Court Of Appeals For The Third Circuit Seeking To Overturn Judge Quraishi's Ruling.

July 2024: Bristol Myers Squibb And Johnson & Johnson Filed An Appeal With The U.S. Court Of Appeals For The Third Circuit Seeking To Overturn Judge Quraishi's Ruling. "On Friday, Johnson & Johnson and Bristol Myers Squibb filed an appeal at the U.S. Court of Appeals for the Third Circuit, arguing that the District Court judge erred in April when he tossed lawsuits by the companies questioning the constitutionality of the Inflation Reduction Act." [FiercePharma, 07/16/24]

Several Organizations That Have Filed Amicus Briefs In Support Of The Appeal Have Received Nearly \$4.8 Million From PhRMA Since 2019.

Amicus Filer	FY 2022 PhRMA Money	FY 2021 PhRMA Money	FY 2020 PhRMA Money	FY 2019 PhRMA Money	TOTALS
Alliance for Aging Research	<u>\$175,000</u>	<u>\$300,000</u>	<u>\$95,000</u>	<u>\$10,000</u>	\$580,000
Biotechnology Innovation Organization	\$0	\$2,814,000	\$122,000	<u>\$1,065,000</u>	\$4,001,000
Manhattan Institute	\$0	\$0	\$0	<u>\$50,000</u>	\$50,000
Washington Legal Foundation	\$40,00 <u>0</u>	<u>\$40,000</u>	\$40,00 <u>0</u>	\$40,00 <u>0</u>	\$160,000

TOTAL: \$4,791,000

Bristol Myers Squibb And Johnson & Johnson Are Also Financially Connected To Several Amicus Filers Through Memberships And Sponsorships.

Bristol Myers Squibb And PhRMA Are Among Several Industry Sponsors Of The Alliance For Aging Research's Upcoming 2024 Heroes In Health Celebration.

Bristol Myers Squibb, PhRMA, And Several Other Pharmaceutical Companies And Groups Are Sponsoring Alliance For Aging Research's Upcoming 2024 Heroes In Health Celebration. [Alliance for Aging Research, accessed 07/23/24]



## **Conversation Supporters**







[Alliance for Aging Research, accessed <u>07/23/24</u>]

Amgen, Whose Enbrel Is One Of The 10 Drugs Up For Medicare Negotiation, Was A Silver Level Sponsor Of The Atlantic Legal Foundation's 2023 Annual Awards Dinner.

Amgen, One Of Several Companies With Drugs Up For Medicare Negotiation, Was A Silver Level Sponsor Of The Atlantic Legal Foundation's 2023 Annual Awards Dinner:




[Atlantic Legal Foundation, accessed <u>07/23/24</u>]


Amgen's Enbrel Is One Of The 10 Drugs Up For Medicare Negotiation. "The drugs that made the
price negotiation cut are Johnson & Johnson's Imbruvica, Stelara and Xarelto plus Bristol Myers
Squibb's Eliquis, Merck & Co.'s Januvia, Novartis' Entresto, Eli Lilly's Jardiance, AstraZeneca's Farxiga,
Novo Nordisk's Fiasp and Amgen's Enbrel." [Fierce Pharma, 08/29/23]

## Bristol Myers Squibb And Johnson & Johnson Are Both Members Of The Biotechnology Innovation Organization.

Bristol Myers Squibb And Johnson & Johnson Are Both Members Of The Biotechnology Innovation Organization:



[BIO, accessed <u>07/23/24</u>]



[BIO, accessed 07/23/24]

Daniel E. Troy Is a Former Member Of GlaxoSmithKline's Corporate Executive Team, Including A Stint As General Counsel "Responsible For Leading The Company's Legal Department In Protecting GSK's Intellectual Property [And] Managing Litigation."

Daniel E. Troy Was A Member Of GlaxoSmithKline's Corporate Executive Team From September 2008 To August 2018, Including A Stint As General Counsel Where He Was "Responsible For Leading The Company's Legal Department In Protecting GSK's Intellectual Property [And] Managing Litigation." "From September 2008 until August 1, 2018, Dan Troy was Senior Vice President & General Counsel and a member of the Corporate Executive Team of GSK. As General Counsel, he was responsible for leading the company's legal department in protecting GSK's intellectual property, managing litigation, supporting business development transactions, as well as risk management." [American Law Institute, accessed 07/23/24]

• Daniel E. Troy Filed An Amicus Brief In Support Of The Appeal. [Georgetown Litigation Tracker, accessed 07/23/24]